Dr Reddy's files petition in US court against stay on generic drug
Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) is meant for the treatment of opioid dependence/addiction.
Dr. Reddy's Laboratories has filed a petition in the US Court of Appeals for the Federal Circuit against the preliminary injunction imposed by another US court preventing the Indian drug-maker from selling the generic Suboxone sublingual film in America.
Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) is meant for the treatment of opioid dependence/addiction. The US Court of Appeals, which said it may hear the petition in the first week of October, had 'granted-in-part' motion to expedite the appeal of Dr. Reddy's.
Based on a petition of Indivior, a specialty pharmaceuticals business listed on the London Stock Exchange, the US court for the district of New Jersey, had, on July 13, granted the preliminary injunction on the launch of Suboxone by Dr. Reddy's which has appealed against the ruling. Indiviorsaid would continue to defend its patent rights to the Suboxone film, including opposing Dr. Reddy's appeal.
Suboxone recorded sales of around $1.86 billion in the US for the year ending April 2018, according to market reports. A senior official of Dr. Reddys had earlier indicated that it sold Suboxone worth over USD 15 million in the US market giving fillip to profit in the first quarter.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)